The Experts below are selected from a list of 65382 Experts worldwide ranked by ideXlab platform

Maryanne M. Senna - One of the best experts on this subject based on the ideXlab platform.

A Morgan - One of the best experts on this subject based on the ideXlab platform.

  • The risk of febrile neutropenia in patients with non-small-cell lung cancer treated with docetaxel: a systematic review and meta-analysis
    British Journal of Cancer, 2009
    Co-Authors: A Wailoo, A Sutton, A Morgan
    Abstract:

    We aimed to assess the incidence of febrile neutropenia in patients with non small cell lung cancer treated with docetaxel as second line Chemotherapy by systematic review and meta-analysis of clinical studies. Published studies were retrieved and included if they considered docetaxel at the licensed dose after a previous Chemotherapy Regimen, and reported the proportion of patients getting FN. Meta-analysis was conducted to estimate the proportion of patients who experience one or more episodes of FN. The pooled, random effects meta-analysis estimate for the proportion of patients who experience one or more episodes of FN on docetaxel was 5.95% (95% CI 4.22–8.31) based on 13 studies, comprising 1609 patients. No significant differences were seen either between studies that permitted the use of prophylactic granulocyte colony-stimulating factors or between phase II and phase III trials. Evidence from randomised controlled trials suggests that the incidence of FN with docetaxel is around 6% and therefore an important factor to consider in the choice of the Chemotherapy Regimen.

John L. Gore - One of the best experts on this subject based on the ideXlab platform.

  • Chemotherapy Regimen is associated with venous thromboembolism risk in patients with urothelial tract cancer.
    BJU international, 2019
    Co-Authors: Jorge Ramos, Sarah K. Holt, George R. Schade, Matthew D. Galsky, Jonathan L. Wright, John L. Gore
    Abstract:

    OBJECTIVE To assess the association of venous thromboembolism (VTE) with different Chemotherapy Regimens in patients with urothelial tract cancer. PATIENTS AND METHODS We identified patients aged ≥66 years, diagnosed with urothelial tract cancer in the period 1998 to 2011 in the Surveillance, Epidemiology, and End Results (SEER) Medicare-linked database. The Chemotherapy Regimens analysed were gemcitabine/cisplatin (GC), methotrexate/vinblastine/doxorubicin/cisplatin (MVAC), or gemcitabine/carboplatin (CarboG). Propensity scores for treatment Regimen based on comorbidities, tumour characteristics, age, and year of diagnosis were calculated. VTE rates within 120 days of Chemotherapy initiation were calculated. VTE risk stratified by Chemotherapy Regimen was modelled using multivariable logistic regression, adjusting for treatment propensity scores and additional demographic characteristics. Overall survival stratified by VTE and Chemotherapy Regimen was estimated using Kaplan-Meier methods and the log-rank test. RESULTS Of 5594 identified patients, a VTE occurred in 13.0%. The VTE rates within 120 days of Chemotherapy initiation were 15.3% for GC, 8.7% for MVAC, and 12.0% for CarboG. On multivariable analysis, MVAC (odds ratio [OR] 0.60, 95% confidence interval [CI] 0.39-0.94) and CarboG (OR 0.71, 95% CI: 0.59-0.85) were associated with lower VTE risk compared with GC. VTE was associated with worse overall survival (P < 0.001). CONCLUSIONS Compared with GC, MVAC and CarboG were associated with a lower rate of VTE. This finding suggests that gemcitabine may add to the increased thrombosis risk from cisplatin. Additionally, patients with a VTE had worse survival outcomes than those without a VTE. Analysis of the risk of blood clots with different Chemotherapy Regimens in patients with urothelial tract cancer showed that GC was associated with the highest rate. We also found that blood clots were associated with worse patient outcomes.

Dustin H. Marks - One of the best experts on this subject based on the ideXlab platform.

Servando Cardona-huerta - One of the best experts on this subject based on the ideXlab platform.

  • Impact of Chemotherapy Regimen and sequence on the effectiveness of scalp cooling for alopecia prevention
    Breast Cancer Research and Treatment, 2020
    Co-Authors: Cynthia Villarreal-garza, Fernanda Mesa-chavez, Ma Ria Alejandra Garza-ledezma, Omar Peña-curiel, Bertha Alejandra Martinez-cannon, Mauricio Canavati-marcos, Servando Cardona-huerta
    Abstract:

    Purpose Scalp cooling (SC) is the most reliable method for the prevention of Chemotherapy-induced alopecia. However, it remains unclear if its effectiveness is related to the Chemotherapy Regimen, sequence, and frequency. This study aims to evaluate SC performance among breast cancer patients who received different Chemotherapy Regimens. Methods The medical records of all consecutive patients undergoing curative-intent Chemotherapy and receiving at least one SC session using the DigniCap® System from 2016–2020 in a private Mexican hospital were retrospectively reviewed. SC effectiveness according to Chemotherapy Regimen was analyzed using descriptive statistics. Successful alopecia prevention was defined as grade 0–1 alopecia (